Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies
Beckley Waves, a U.K.-based venture studio co-founded by “Queen of Psychedelics” Amanda Feilding with angel investors like FJ Labs, Courtney & Carter Reum, Joanne Wilson, and actress Rosamund Pike, recently closed a funding round of $3.3 million (+10% more than the original target). The company believes that the increased interest from investors in care delivery and expanded access signifies the end of the “psychedelic winter.”
The funding round included participation from several family and VC mission-aligned offices such as the Joe & Sandy Samberg Foundation, Satori Neuro, Bridge Builders Collaborative, Evolve Ventures and Foundation, 1440 Foundation, Austin Hearst, and Asia Agnelli.
Amanda Feilding emphasizes the importance of scaling up safe and legal access to psychedelics as public interest in their benefits grows. She states that Beckley Waves already has a strong track record of founding and investing in startups that are building the care-delivery infrastructure. The new funding will enable them to continue this important work. The company has previously co-founded Beckley Retreats, the Beckley Academy, and The Trip Report, all of which contribute to expanding access to psychedelic therapies.
This funding will also allow Beckley Waves to make strategic investments in early-stage teams and provide support and guidance for successful seed rounds.
Israeli Biotech’s Public Offering
Clearmind Medicine CMND is pricing its U.S.-only public offering, with anticipated gross proceeds of approximately $2.25 million. The offering is expected to close on September 18. Clearmind Medicine focuses on the discovery and development of novel psychedelic-derived therapeutics to address major undertreated health conditions, particularly alcohol use disorder.
The public offering includes 7,500,000 common shares and pre-funded warrants, as well as 7,500,000 common warrants. The common warrants are exercisable immediately and have a five-year expiration date from issuance, with an exercise price of $0.30 per common share.
Each common share (or replacing pre-funded warrant) will be sold with one common warrant at a combined purchase unit price of $0.30, but they will be issued separately. The common warrants and pre-funded warrants will not be listed on any exchange.
Clearmind Medicine has appointed Aegis Capital as its exclusive placement agent and filed a registration statement on Form F-1 with the U.S. SEC, which became effective on September 14, 2023. The offering is not available to Canadian investors.
Ready for Benzinga’s Cannabis Capital Conference? Come join us at the 17th edition of our biannual, crowd-puller event where deals get done, this September 27-28. Get your tickets today and secure your spot at the epicenter of cannabis investment and branding!
Photo: Benzinga edit with photo by PublicDomainPictures and janjf93 on Pixabay.
